Anti-HER-2 therapies and left ventricular dysfunction the renaissance study
Andrés J. Daniele(Asociación por los Derechos Civiles), M.V. Cáceres, G. Roganovich, Angie Pauleth Tinoco Aguilar, Vanesa Gregorietti, Nicholas Kassis, Venus Maria Tapia Lopez, M. Savignano, A D ́ Ortencio, S. Daniele(Hospital Italiano de Buenos Aires), Cecilia Almada
Cited by 0
Related Papers
Cardiovascular Manifestations From Therapeutic Radiation
|JACC CardioOncology|2021|201
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
|Cardio-Oncology|2020|59
Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial
|Cardio-Oncology|2024|32
Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey
|Cardio-Oncology|2020|28
Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building
|Current Oncology Reports|2021|19